Valneva SE
VALN Nasdaq Biological Products, (No Diagnostic Substances) 金融 FY2019–FY2025
Valneva SE 的业务
暂无业务介绍。
- 法定名称
- Valneva SE
- 财年结束日
- 2025年12月31日
- 最新年报
- 20-F · 2026年3月17日
- 登记号 · CIK
- 0001628280-26-018808
0001836564
营收与利润率
Valneva SE 在 2025 财年 营收为 $197M,同比增长 7.4%。
净利润与每股收益
亏损期间以红色显示。
资本回报率
税后营业利润占投入业务资金(债务加股东权益减现金)的比例。
现金流
2025 财年 的自由现金流为 −$64.6M,占营收的 −32.8%。 经营现金流减资本支出。
股息、回购与股数
Valneva SE 在 2025 财年 向股东返还 —。 稀释股数增加 15.4%。
资产负债表
现金、债务以及显示 Valneva SE 承担债务能力的指标。
| 财年末 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| 现金及短期投资 | $393M | $306M | $139M | $175M | $129M |
| 债务(含融资租赁) | $65.5M | $105M | $195M | $195M | $211M |
| 净债务 / EBITDA | — | — | — | 0.6x | — |
| 债务 / 股东权益 | 0.3x | 0.4x | 1.4x | 1.0x | 1.7x |
| 利息保障倍数 | −3.6x | −6.0x | −3.5x | 0.6x | −2.0x |
| 流动比率 | 1.6x | 1.5x | 1.7x | 2.6x | 2.4x |
| 速动比率 | 1.3x | 1.4x | 1.4x | 2.1x | 1.8x |
| 总资产 | $926M | $663M | $508M | $519M | $469M |
| 总负债 | $733M | $428M | $367M | $331M | $344M |
| 股东权益 | $193M | $234M | $142M | $188M | $125M |
| 净债务 (− = 净现金) | −$327M | −$200M | $56.1M | $19.8M | $81.7M |
内部人交易
高管、董事和持股超过 10% 的股东在公开市场的买卖,数据来自 Form 4 申报。“计划”表示依据事先制定的 Rule 10b5-1 计划进行的交易。
买入(12 个月)
$0.0M
0 名内部人士
卖出(12 个月)
$0.0M
0 名内部人士
卖出中按计划执行的比例
—
$0.0M
过去 12 个月没有公开市场的内部人交易。
Piotroski F 分数
关于盈利能力、融资和效率的九项通过/未通过测试。8–9 为强,0–2 为弱。
| 测试项 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| 净利润为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流为正 | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ |
| 资产回报率上升 | — | — | ✓ | ✕ | ✓ | ✓ | ✕ |
| 经营现金流高于净利润 | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ | ✓ |
| 债务相对资产下降 | — | — | ✓ | ✕ | ✕ | ✓ | ✕ |
| 流动比率上升 | — | — | ✕ | ✕ | ✓ | ✓ | ✕ |
| 股数未增加 | — | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 毛利率上升 | — | ✕ | ✕ | ✕ | ✓ | ✓ | ✕ |
| 营收相对资产上升 | — | — | ✓ | ✓ | ✕ | ✓ | ✓ |
| F 分数 | — / 3 | — / 5 | 5 / 9 | 1 / 9 | 3 / 9 | 5 / 9 | 2 / 9 |
| 应计比率 | — | −39.9% | −22.1% | 13.5% | 18.7% | 11.6% | −14.2% |
| Altman Z'' | — | — | — | — | — | — | — |
7 年数据
金额单位为 USD。将鼠标悬停在指标名称上可查看定义。
| 财年 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| 利润表 | |||||||
| 营收 | $141M | $126M | $412M | $380M | $166M | $183M | $197M |
| 毛利 | $82.2M | $63.9M | $189M | $38.7M | $57.1M | $76.9M | $76.1M |
| 研发支出 | $42.6M | $96.3M | $205M | $110M | $64.8M | $80.2M | $96.2M |
| 营业利润 | −$0.9M | −$62.8M | −$72.6M | −$119M | −$88.8M | $14.4M | −$92.5M |
| 利息支出 | $3.4M | $12.2M | $20.1M | $20.0M | $25.2M | $25.9M | $47.2M |
| 税前利润 | −$1.0M | −$74.4M | −$82.8M | −$152M | −$107M | −$12.4M | −$129M |
| 所得税 | $1.0M | −$1.0M | $4.1M | −$1.6M | $3.0M | $0.8M | $1.2M |
| 净利润 | −$0.9M | −$62.8M | −$72.6M | −$151M | −$110M | −$13.2M | −$130M |
| 归属普通股股东的净利润 | −$0.9M | −$62.8M | −$72.6M | — | — | — | — |
| 稀释每股收益 | −$0.04 | −$1.62 | −$1.77 | −$2.61 | −$1.58 | −$0.17 | −$1.53 |
| 稀释股数 | 0.05B | 0.05B | 0.05B | 0.06B | 0.07B | 0.07B | 0.08B |
| 现金流 | |||||||
| 经营现金流 | $6.2M | $157M | $90.9M | −$258M | −$219M | −$72.7M | −$59.6M |
| 资本支出 | $11.8M | $21.6M | $109M | $30.7M | $15.4M | $15.0M | $5.0M |
| 自由现金流 | −$5.6M | $135M | −$18.1M | −$289M | −$235M | −$87.7M | −$64.6M |
| 折旧与摊销 | — | $11.2M | $16.9M | $22.1M | $19.0M | $21.2M | $24.5M |
| 股权激励 | — | $7.2M | $17.2M | −$9.1M | $5.5M | $8.6M | $10.7M |
| 收购 | — | — | $0.0M | $0.0M | $11.8M | $0.0M | $0.0M |
| 资产负债表 | |||||||
| 现金及短期投资 | $72.4M | $251M | $393M | $306M | $139M | $175M | $129M |
| 总债务 | $29.6M | $65.5M | $65.5M | $105M | $195M | $195M | $211M |
| 流动资产 | — | $378M | $664M | $453M | $290M | $311M | $261M |
| 流动负债 | — | $216M | $418M | $296M | $176M | $119M | $110M |
| 存货 | — | $33.0M | $141M | $37.4M | $49.1M | $55.8M | $59.0M |
| 固定资产净额 | $22.5M | $42.7M | $142M | $120M | $150M | $144M | $140M |
| 无形资产 | $47.0M | $43.5M | $37.0M | $30.6M | $28.3M | $26.2M | $26.3M |
| 总资产 | — | $551M | $926M | $663M | $508M | $519M | $469M |
| 总负债 | — | $456M | $733M | $428M | $367M | $331M | $344M |
| 股东权益 | $152M | $95.0M | $193M | $234M | $142M | $188M | $125M |
| 利润率 | |||||||
| 毛利率 | 58.2% | 50.8% | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| 营业利润率 | −0.6% | −50.0% | −17.6% | −31.4% | −53.4% | 7.9% | −47.0% |
| EBITDA 利润率 | — | −41.1% | −13.5% | −25.6% | −42.0% | 19.4% | −34.5% |
| 净利率 | −0.6% | −50.0% | −17.6% | −39.7% | −66.0% | −7.2% | −66.0% |
| 自由现金流利润率 | −3.9% | 107.7% | −4.4% | −76.0% | −141.2% | −47.8% | −32.8% |
| 回报率 | |||||||
| 资本回报率 | −0.7% | — | — | −275.4% | −35.5% | 5.5% | −35.4% |
| 已动用资本回报率 | — | −18.7% | −14.3% | −32.5% | −26.7% | 3.6% | −25.8% |
| 股本回报率 | −0.6% | −50.9% | −50.4% | −70.4% | −58.3% | −8.0% | −83.0% |
| 资产回报率 | — | −11.4% | −9.8% | −19.0% | −18.7% | −2.6% | −26.3% |
| 有形股本回报率 | −0.9% | −121.9% | −46.5% | −73.9% | −96.7% | −8.2% | −131.9% |
| 增长 | |||||||
| 营收增长 | — | −11.0% | 227.4% | −7.8% | −56.2% | 10.4% | 7.4% |
| 自由现金流增长 | — | — | −113.4% | — | — | — | — |
| 股数变化 | — | −1.1% | 7.6% | 18.3% | 20.0% | 5.1% | 15.4% |
| 财务健康 | |||||||
| 净债务 / EBITDA | — | — | — | — | — | 0.6x | — |
| 债务 / 股东权益 | 0.2x | 0.7x | 0.3x | 0.4x | 1.4x | 1.0x | 1.7x |
| 利息保障倍数 | −0.3x | −5.1x | −3.6x | −6.0x | −3.5x | 0.6x | −2.0x |
| 流动比率 | — | 1.8x | 1.6x | 1.5x | 1.7x | 2.6x | 2.4x |
| 速动比率 | — | 1.6x | 1.3x | 1.4x | 1.4x | 2.1x | 1.8x |
| 资本配置 | |||||||
| 资本支出 / 营收 | 8.3% | 17.2% | 26.5% | 8.1% | 9.3% | 8.2% | 2.5% |
| 股权激励 / 营收 | — | 5.7% | 4.2% | −2.4% | 3.3% | 4.7% | 5.5% |
| 质量评分 | |||||||
| Piotroski F 分数 | — | — | 5.0 | 1.0 | 3.0 | 5.0 | 2.0 |
| 应计比率 | — | −39.9% | −22.1% | 13.5% | 18.7% | 11.6% | −14.2% |
来源:SEC EDGAR XBRL 文件 (CIK 0001836564). 数据更新于 2026年10月24日。 第四季度数据为全年减去前九个月。 以 EUR 按 IFRS 申报,并换算为美元:损益和现金流项目按各期平均汇率换算,资产负债表项目按期末汇率换算。 每股数据按美国上市股份计算(1 份 ADS = 2 股普通股)。 仅供参考,不构成投资建议。依赖任何数字前,请核对原始文件。
